Lonza Group Ltd (LZAGY)
OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous close | 65.90 |
| Open | 65.58 |
| Bid | 65.79 x 40000 |
| Ask | 65.89 x 40000 |
| Day's range | 65.58 - 66.04 |
| 52-week range | 34.19 - 66.04 |
| Volume | |
| Avg. volume | 34,382 |
| Market cap | 47.569B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | 73.14 |
| EPS (TTM) | 0.90 |
| Earnings date | 14 May 2024 |
| Forward dividend & yield | 0.44 (0.67%) |
| Ex-dividend date | 15 May 2024 |
| 1y target est | 66.20 |
ReutersSwiss pharma firm Lonza's profit falls less than feared, shares rise
(Reuters) -Swiss contract drug manufacturer Lonza reported a smaller-than-expected decline in first-half profit on Thursday, as a strong performance in its core Biologics unit partly offset weak demand for capsules. Analysts at J.P. Morgan said the results may imply an upside potential to the annual core earnings margin guidance, and therefore expect shares to outperform. Lonza's Biologics unit produces monoclonal antibodies and drug conjugates, and comprises approximately 45% of its annual sales.
ZacksESLOY or LZAGY: Which Is the Better Value Stock Right Now?
ESLOY vs. LZAGY: Which Stock Is the Better Value Option?
- GuruFocus.com
Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Explore key insights from Acumen Pharmaceuticals' Q1 2024 earnings, focusing on their innovative Alzheimer's treatments and financial outlook.
© 2024 Yahoo. All rights reserved.